{"pmid":32344070,"pmcid":"PMC7194643","title":"Calm before the storm: understanding the role of JAK inhibitors in COVID-19.","text":["Calm before the storm: understanding the role of JAK inhibitors in COVID-19.","J Am Acad Dermatol","Peterson, Danielle","Damsky, William","King, Brett","32344070"],"journal":"J Am Acad Dermatol","authors":["Peterson, Danielle","Damsky, William","King, Brett"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344070","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.jaad.2020.04.097","keywords":["covid-19","jak","janus kinase inhibitors","sars-cov-2","autoimmune disease","coronavirus","general dermatology","immunomodulators","immunosuppressants","medical dermatology"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495041667074,"score":9.490897,"similar":[{"pmid":32278797,"pmcid":"PMC7144601","title":"The use of Janus kinase inhibitors in the time of SARS-CoV-2.","text":["The use of Janus kinase inhibitors in the time of SARS-CoV-2.","J Am Acad Dermatol","Peterson, Danielle","Damsky, William","King, Brett","32278797"],"journal":"J Am Acad Dermatol","authors":["Peterson, Danielle","Damsky, William","King, Brett"],"date":"2020-04-13T11:00:00Z","year":2020,"_id":"32278797","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.jaad.2020.03.099","keywords":["covd-19","janus kinase inhibitors","sars-cov-2","autoimmune disease","coronavirus","general dermatology","immunomodulators","immunosuppressants","medical dermatology"],"topics":["Treatment"],"weight":1,"_version_":1666138491589754880,"score":315.10114},{"pmid":32376422,"pmcid":"PMC7196541","title":"Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern.","text":["Cyclosporine therapy during the COVID-19 pandemic is not a reason for concern.","J Am Acad Dermatol","Rudnicka, Lidia","Goldust, Mohamad","Glowacka, Paulina","Sikora, Mariusz","Sar-Pomian, Marta","Rakowska, Adriana","Samochocki, Zbigniew","Olszewska, Malgorzata","32376422"],"journal":"J Am Acad Dermatol","authors":["Rudnicka, Lidia","Goldust, Mohamad","Glowacka, Paulina","Sikora, Mariusz","Sar-Pomian, Marta","Rakowska, Adriana","Samochocki, Zbigniew","Olszewska, Malgorzata"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376422","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jaad.2020.04.153","keywords":["covid-19","autoimmune disease","cyclosporine","dermatology","immunosuppressants","virus"],"e_drugs":["Cyclosporine"],"topics":["Treatment"],"weight":1,"_version_":1666596532358479872,"score":99.92316},{"pmid":32255510,"title":"COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement.","text":["COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement.","Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cutaneous disease, represent a potentially vulnerable population during the COVID-19 pandemic. There is currently insufficient evidence to determine whether patients on systemic immunomodulators are at increased risk of developing COVID-19 disease or more likely to have severe disease. As such, clinicians need to assess the benefit-to-risk ratio on a case-by-case basis. In patients with suspected or confirmed COVID-19 disease, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of systemic corticosteroid therapy, which needs to be weaned. In patients who develop symptoms or signs of an upper respiratory tract infection, but COVID-19 is not yet confirmed, consider dose reduction or temporarily cessation for 1-2 weeks. In otherwise well patients, immunomodulators and biologics should be continued. In all patients, and their immediate close contacts, the importance of preventative measures to minimise human-to-human transmission cannot be overemphasised.","Australas J Dermatol","Wang, Charlie","Rademaker, Marius","Baker, Christopher","Foley, Peter","32255510"],"abstract":["Patients on immunomodulators, including biologic agents and new small molecular inhibitors, for cutaneous disease, represent a potentially vulnerable population during the COVID-19 pandemic. There is currently insufficient evidence to determine whether patients on systemic immunomodulators are at increased risk of developing COVID-19 disease or more likely to have severe disease. As such, clinicians need to assess the benefit-to-risk ratio on a case-by-case basis. In patients with suspected or confirmed COVID-19 disease, all immunomodulators used for skin diseases should be immediately withheld, with the possible exception of systemic corticosteroid therapy, which needs to be weaned. In patients who develop symptoms or signs of an upper respiratory tract infection, but COVID-19 is not yet confirmed, consider dose reduction or temporarily cessation for 1-2 weeks. In otherwise well patients, immunomodulators and biologics should be continued. In all patients, and their immediate close contacts, the importance of preventative measures to minimise human-to-human transmission cannot be overemphasised."],"journal":"Australas J Dermatol","authors":["Wang, Charlie","Rademaker, Marius","Baker, Christopher","Foley, Peter"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32255510","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1111/ajd.13313","keywords":["covid-19","janus kinase inhibitors","biologic agents","biologics","ciclosporin","dermatolology","immunomodulators","methotrexate","systemic steroids"],"locations":["Australian","New Zealand"],"countries":["Australia","New Zealand"],"countries_codes":["AUS|Australia","NZL|New Zealand"],"topics":["Prevention"],"weight":1,"_version_":1666138493155278848,"score":92.99292},{"pmid":32385052,"title":"HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.","text":["HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.","JAK kinase inhibitors are being investigated as a way of managing cytokine storm in severe COVID-19 patients.","Sci Immunol","Spinelli, Francesca Romana","Conti, Fabrizio","Gadina, Massimo","32385052"],"abstract":["JAK kinase inhibitors are being investigated as a way of managing cytokine storm in severe COVID-19 patients."],"journal":"Sci Immunol","authors":["Spinelli, Francesca Romana","Conti, Fabrizio","Gadina, Massimo"],"date":"2020-05-10T11:00:00Z","year":2020,"_id":"32385052","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1126/sciimmunol.abc5367","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666340101978849280,"score":72.502075},{"pmid":32468151,"title":"The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?","text":["The unleashing of the immune system in COVID-19 and sepsis: the calm before the storm?","The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.","Inflamm Res","Bellinvia, Salvatore","Edwards, Christopher J","Schisano, Matteo","Banfi, Paolo","Fallico, Matteo","Murabito, Paolo","32468151"],"abstract":["The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response."],"journal":"Inflamm Res","authors":["Bellinvia, Salvatore","Edwards, Christopher J","Schisano, Matteo","Banfi, Paolo","Fallico, Matteo","Murabito, Paolo"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32468151","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s00011-020-01366-6","keywords":["checkpoint inhibitors","covid-19","cytokine storm","immune dysregulation","inflammatory receptors","sepsis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668420887162912768,"score":70.11563}]}